Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Vertex Pharmaceuticals

CTX001 continues to help patients with transfusion-dependent beta thalassemia and sickle cell disease.

CRISPR and Vertex Release Additional Data for Blood Disease Treatment

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data in seven patients from two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9 gene-editing therapy CTX001 in severe hemoglobinopathies has been accepted for an oral presentation during the Plenary Scientific Session at the annual ASH Meeting and Exposition, which will take place virtually from December 5-8, 2020. Haydar Frangoul, M.D., Medical Director of Pediatric Hematology and Oncology at Sarah Cannon Research Institute, HCA Healthcare's TriStar Centennial Medical Center, will deliver the presentation on behalf of all the authors on December 6, 2020.

CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition

Its approach to cell therapy is lucrative and immensely powerful for patients.

Despite Recent Bad News, Here's Why CRISPR Is Primed to Explode

Arrowhead Pharmaceuticals

These biotechs are fueling up for massive market launches.

2 Monster Young Biotech Stocks to Add to Your Watchlist

The company flipped to a bottom-line loss for the period.

CRISPR Therapeutics Stock Falls 3.5% on Q3 Results

-Reported positive top-line results from the Company's ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110™, targeting CD19+ B-cell malignancies-

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results

Apple

Citrix Systems

MercadoLibre

PayPal

Seagen

Tesla

Most Nasdaq stocks have seen ups and downs this year. But these seven have weathered the pandemic well and are bound to climb higher soon.

7 Strong Nasdaq Stocks to Buy As They Keep Marching Higher

Early signs of success with a revolutionary new type of cancer treatment make this biotech worth a closer look.

Is CRISPR Therapeutics a Good Biotech Stock to Buy Now?

One analyst goes contrarian, raising her price target on the stock following some very dispiriting news from the company.

Is CRISPR Therapeutics Really Headed to $110?

CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.

CRISPR (CRSP) Falls Despite Positive Data on Lymphoma Study

The death of a clinical trial participant overshadowed clear signs of efficacy for the company's off-the-shelf cellular therapy for non-Hodgkin lymphoma.

CRISPR Therapeutics Reports Mixed Cancer Trial Results

A patient death in an early stage cancer trial is unnerving investors.

Why CRISPR Therapeutics Stock Sank Today

Crispr Therapeutics (CRSP) news for Wednesday includes a patient's death during a recent drug trial dropping CRSP stock down. The post Crispr Therapeutics News: CRSP Stock Slides 12% on Trial Death appeared first on InvestorPlace.

Crispr Therapeutics News: CRSP Stock Slides 12% on Trial Death

Crispr Therapeutics said a patient in a Phase 1 clinical trial of a CAR-T therapy to treat a type of B-cell lymphoma died 52 days after infusion, sending CRSP stock plunging early Wednesday. The post Crispr Therapeutics Reports A Patient Death In Lymphoma Therapy Clinical Trial appeared first on Investor's Business Daily.

Crispr Therapeutics Reports A Patient Death In Lymphoma Therapy Clinical Trial

- 50% (2/ 4 ) complete response (CR) rate at three months in the Dose Level 3 (DL3) cohort; b oth responders remain in CR -

CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies

iShares Nasdaq Biotechnology ETF

Moderna

Regardless of lockdowns or otherwise, these biotech stocks are positioned to rally strongly in the weeks and months ahead The post 3 Biotech Stocks to Buy Right Now appeared first on InvestorPlace. More From InvestorPlace Forget The Election… Pick These Stocks for the Win in 2021 Why Everyone Is Investing in 5G All WRONG America's #1 Stock Picker Reveals His Next 1,000% Winner Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company

3 Biotech Stocks to Buy Right Now

Shares of Crispr Therapeutics AG CRSP, +7.84% shot up 7.9% in midday trading Monday, after a bullish call from BofA Securities analyst Geoff Meacham, who suggested a target that was 28% above current levels and 9.3% above the Aug. 19 record close of $100.64.

Crispr's stock shoots up after bullish call from BofA Securities analyst

CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals' CRISPR/Cas9 gene-editing therapy candidate, CTX001, gets Priority Medicines designation for treating sickle cell disease.

CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status

As a premier gene-editing company, CRISPR delivered stellar animal data for the blood disorder franchises (i.e., beta-thalassemia and sickle cell disease).

Crispr: The Frontier Of Gene Editing

Vaxart

From a painless vaccine to a method of fixing faulty genes, betting on these technologies may bring big rewards.

2 Game-Changing Biotech Stocks That May Make You Rich

Editas Medicine

Intellia Therapeutics

Sangamo Therapeutics

Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?

CRISPR Stocks: Buy or Trade?

CRSP stock has pulled back 13% in the last two sessions — on no news. The dip allows investors into a strong long-term story at a lower price.

CRISPR Therapeutics Stock Is a Strong Buy on the Dip

The stock may not fall from its new highs anytime soon.

Is CRISPR Therapeutics Stock a Good Buy Now, or Is It Too Late?

Invitae

Here's how a sector fund can help you find top stocks in sizzling sectors. They’re a great place to start, especially when you want to gain exposure to a specific hypergrowth trend.

How to Find the Top Stocks in the Hottest Sectors

ZUG, Switzerland and CAMBRIDGE, Mass., Sept.  03, 2020  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020, at 11:20 a.m. ET.

News for CRISPR Therapeutics Stock (CRSP)